EXTAVIA

This brand name is authorized in Austria, Brazil, Canada, Croatia, Cyprus, Estonia, France, Ireland, Lithuania, Poland, Spain, UK.

Active ingredients

The drug EXTAVIA contains one active pharmaceutical ingredient (API):

1	Interferon-beta 1B recombinant UNII TTD90R31WZ - INTERFERON BETA-1B
	Interferon beta-1b has been shown to possess both antiviral and immunoregulatory activity. The mechanisms by which interferon beta-1b exerts its actions in multiple sclerosis are not clearly understood. However, it is known that the biological response-modifying properties of interferon beta-1b are mediated through its interactions with specific cell receptors found on the surface of human cells.
	Read more about Interferon beta-1b

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
EXTAVIA Powder and solvent for solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L03AB08	Interferon beta-1b	L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AB Interferons
Discover more medicines within L03AB08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	526514120080103
CA	Health Products and Food Branch	02337819
EE	Ravimiamet	1361382, 1361393, 1480137, 1480148, 1480159
ES	Centro de información online de medicamentos de la AEMPS	108454008
FR	Base de données publique des médicaments	64851088
GB	Medicines & Healthcare Products Regulatory Agency	154037
LT	Valstybinė vaistų kontrolės tarnyba	1070395, 1070396, 1070397, 1070398, 1070399, 1080528, 1080529
PL	Rejestru Produktów Leczniczych	100195390